Clinical Development of Anti-mitotic Drugs in Cancer. (Q39363642)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28600785 AND SRC:MED&resulttype=core&format=json

22 March 2020

review article

1 reference

title

Clinical Development of Anti-mitotic Drugs in Cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28600785 AND SRC:MED&resulttype=core&format=json

22 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28600785 AND SRC:MED&resulttype=core&format=json

22 March 2020

author name string

Anna-Maria Olziersky

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28600785 AND SRC:MED&resulttype=core&format=json

22 March 2020

language of work or name

English

0 references

publication date

1 January 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28600785 AND SRC:MED&resulttype=core&format=json

Advances in Experimental Medicine and Biology

22 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28600785 AND SRC:MED&resulttype=core&format=json

22 March 2020

volume

1002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28600785 AND SRC:MED&resulttype=core&format=json

22 March 2020

page(s)

125-152

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28600785 AND SRC:MED&resulttype=core&format=json

Chromosomal instability and aneuploidy in cancer: from yeast to man

22 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Microtubule attachment and spindle assembly checkpoint signalling at the kinetochore

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Microtubule polymerization dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Control of microtubule organization and dynamics: two ends in the limelight

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

How do microtubule-targeted drugs work? An overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

The development of androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Androgen receptor on the move: boarding the microtubule expressway to the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

New paradigms in microtubule-mediated endocrine signaling in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

The pharmacological bases of the antiangiogenic activity of paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Low-dose metronomic paclitaxel chemotherapy suppresses breast tumors and metastases in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

The anti-angiogenic basis of metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Weekly paclitaxel in the adjuvant treatment of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Mechanisms of Taxol resistance related to microtubules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NC

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Targeting the microtubules in breast cancer beyond taxanes: the epothilones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Microtubule-binding agents: a dynamic field of cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Cellular and molecular effects of metronomic vinorelbine and 4-O-deacetylvinorelbine on human umbilical vein endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Multidrug resistance mediated by the multidrug resistance protein (MRP) gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Depletion of JMJD5 sensitizes tumor cells to microtubule-destabilizing agents by altering microtubule stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

βII-tubulin and βIII-tubulin mediate sensitivity to peloruside A and laulimalide, but not paclitaxel or vinblastine, in human ovarian carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Peloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Antibody-drug conjugates as novel anti-cancer chemotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Shared and separate functions of polo-like kinases and aurora kinases in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Targeting polo-like kinase 1 for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Polo-like kinase-1 in DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Polo-like kinase 1 is essential for early embryonic development and tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcom

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Chromosome- and spindle-pole-derived signals generate an intrinsic code for spindle position and orientation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Regulation of NDR1 activity by PLK1 ensures proper spindle orientation in mitosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

PLK1-dependent activation of LRRK1 regulates spindle orientation by phosphorylating CDK5RAP2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Mitotic Control of Planar Cell Polarity by Polo-like Kinase 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

SPAT-1/Bora acts with Polo-like kinase 1 to regulate PAR polarity and cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

PAR proteins direct asymmetry of the cell cycle regulators Polo-like kinase and Cdc25.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Current clinical trials with polo-like kinase 1 inhibitors in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Integrated genomic analyses of ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Polo-like kinase-1 phosphorylates MDM2 at Ser260 and stimulates MDM2-mediated p53 turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

The Dawn of Aurora Kinase Research: From Fly Genetics to the Clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

A gene atlas of the mouse and human protein-encoding transcriptomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

The cellular geography of aurora kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Aurora A is essential for early embryonic development and tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Genetic disruption of aurora B uncovers an essential role for aurora C during early mammalian development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Aurora Kinase A expression is associated with lung cancer histological-subtypes and with tumor de-differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Cre-loxP-controlled periodic Aurora-A overexpression induces mitotic abnormalities and hyperplasia in mammary glands of mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Overexpression of Aurora-A potentiates HRAS-mediated oncogenic transformation and is implicated in oral carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

A genetic variant of Aurora kinase A promotes genomic instability leading to highly malignant skin tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Cross-Talk between AURKA and Plk1 in Mitotic Entry and Spindle Assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Polo-like kinase-activating kinases: Aurora A, Aurora B and what else?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

A functional interplay between Aurora-A, Plk1 and TPX2 at spindle poles: Plk1 controls centrosomal localization of Aurora-A and TPX2 spindle association.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Bora and Aurora-A continue to activate Plk1 in mitosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Linking cell cycle to asymmetric division: Aurora-A phosphorylates the Par complex to regulate Numb localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Aurora A kinase regulates proper spindle positioning in C. elegans and in human cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

NuMA Phosphorylation by Aurora-A Orchestrates Spindle Orientation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Aurora A kinase regulates mammary epithelial cell fate by determining mitotic spindle orientation in a Notch-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

The aurora kinases in cell cycle and leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Crosstalk between Aurora-A and p53: frequent deletion or downregulation of Aurora-A in tumors from p53 null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Mitosis as an anti-cancer drug target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Overexpression of Aurora B is associated with poor prognosis in epithelial ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Aurora B kinase expression in laryngeal squamous cell carcinoma and its prognostic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Aurora kinase A (AURKA) expression in colorectal cancer liver metastasis is associated with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Aurora B Overexpression Causes Aneuploidy and p21Cip1 Repression during Tumor Development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Aurora B prevents delayed DNA replication and premature mitotic exit by repressing p21(Cip1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

ENMD-2076 Is an Orally Active Kinase Inhibitor with Antiangiogenic and Antiproliferative Mechanisms of Action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Mitotic spindle organization by a plus-end-directed microtubule motor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

The bipolar mitotic kinesin Eg5 moves on both microtubules that it crosslinks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Mitotic functions of kinesin-5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Inhibition of Eg5 acts synergistically with checkpoint abrogation in promoting mitotic catastrophe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Kinesin-5 inhibitor resistance is driven by kinesin-12

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Resistance is not futile: Surviving Eg5 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Cyclin-like accumulation and loss of the putative kinetochore motor CENP-E results from coupling continuous synthesis with specific degradation at the end of mitosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Centromere-associated protein E: a motor that puts the brakes on the mitotic checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

CENP-E forms a link between attachment of spindle microtubules to kinetochores and the mitotic checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Gene silencing of CENP-E by small interfering RNA in HeLa cells leads to missegregation of chromosomes after a mitotic delay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Antitumor activity of an allosteric inhibitor of centromere-associated protein-E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Unstable kinetochore-microtubule capture and chromosomal instability following deletion of CENP-E

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Discovery of the First Potent and Selective Inhibitor of Centromere-Associated Protein E: GSK923295.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

Specific Growth Rate versus Doubling Time for Quantitative Characterization of Tumor Growth Rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/978-3-319-57127-0_6

10.1007/978-3-319-57127-0_6

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28600785 AND SRC:MED&resulttype=core&format=json

22 March 2020

1 reference